FitLife Brands, Inc. — Q1 2014 Form 10-Q Summary
Business Context and Reporting Period
FitLife Brands, Inc. develops and distributes nutritional supplements under the NDS, PMD, SirenLabs, and CoreActive brands, primarily through franchised GNC stores in the United States and internationally. The unaudited interim report covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013. The company was a small reporting company and traded under ticker FTLF on the OTCBB.
Key Financial Metrics
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $6.333 million | $6.061 million |
| Gross profit | $2.357 million | $2.270 million |
| Gross margin | 37.2% | 37.5% |
| Operating income | $926,636 | $603,286 |
| Operating margin | 14.6% | 10.0% |
| Net income | $893,346 | $587,415 |
| Net margin | 14.1% | 9.7% |
| Basic diluted EPS | $0.11 / $0.10 | $0.01 / $0.01 |
| Cash flow from operations | $72,242 | $(127,540) |
Cash was $3.307 million at March 31, 2014, essentially unchanged from December 31, 2013. Total current assets were $8.726 million versus current liabilities of $2.243 million, implying a current ratio of approximately 3.9. Accounts receivable increased to $2.676 million from $1.260 million at year-end, while inventory declined to $1.926 million from $2.753 million.
Total debt and advances were $2.752 million, consisting of a $437,089 revolving line of credit and a $2.315 million term loan. The revolving facility matured May 15, 2014 and was secured by eligible receivables and inventory. Long-term debt was $1.821 million. Stockholders’ equity increased to $5.871 million from $4.809 million, primarily reflecting quarterly earnings and equity issued for services.
Material Changes Versus the Prior Comparable Period
- Revenue increased 4.5%, driven by stronger domestic demand, particularly late in the quarter.
- Gross profit increased 3.8%, while gross margin declined modestly from approximately 37.5% to 37.2%.
- Operating income increased approximately 54%, reflecting lower general and administrative expense and lower selling and marketing expense.
- General and administrative expense declined to $805,228 from $997,743, primarily due to lower personnel costs.
- Selling and marketing expense declined to $568,366 from $610,089, principally due to lower sample-pack costs.
- Net income increased approximately 52% to $893,346. The improvement also benefited from $87,500 of other income and a $137,500 gain associated with obtaining full ownership of certain intellectual property, partly offset by a $50,000 write-off of the remaining YogaEarth investment.
- Operating cash flow improved to $72,242 from cash used of $127,540, but accounts receivable growth consumed $1.416 million of cash.
- The company repaid $120,862 of notes payable during the quarter and made no new financing investments.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management did not provide quantified financial guidance. It expects operating cash flow and existing cash resources to fund liquidity needs for the next 12 months. Management expects continued growth from adding GNC stores and approved products, with international expansion viewed as a potential future growth driver.
Sales during the quarter were affected by customer inventory building ahead of the planned transition to GNC’s centralized distribution platform, which became effective May 1, 2014. Management characterized the effect as short-term and expected it to extend no later than June 30, 2014. The company was evaluating the transition’s impact on cost structure but expected operating efficiencies to mitigate potential cost increases.
Material unusual items included the intellectual-property settlement and acquisition, the $137,500 gain on the transaction, the $50,000 YogaEarth investment write-off, and $86,335 of expense for 37,334 shares issued for services. The company also filed a patent application for the acquired intellectual property.
Two patent-related disputes were settled during the quarter. The settlements with Thermolife and Tawnsaura required fees that management considered immaterial; the Tawnsaura settlement also secured a license for use of Citrulline. Management reported no other litigation expected to have a material adverse effect.
Key risks include reliance on key customers, including GNC, competition, market demand, product performance, supplier relationships, personnel retention, and potential changes in accounting rules. The company maintained a $689,000 deferred tax asset and disclosed approximately $20.325 million of federal net operating loss carryforwards, subject to potential utilization limits including Section 382 restrictions.
Management concluded that disclosure controls and internal control over financial reporting were effective as of March 31, 2014. The interim financial statements were reviewed, unaudited, and not a complete presentation of annual GAAP financial statements.
Important Facts for Investors to Verify
- Whether the GNC centralized distribution transition affected revenue, margins, receivables, inventory, and customer ordering after June 30, 2014.
- The maturity, renewal, repayment, or refinancing status of the $437,089 revolving credit facility due May 15, 2014.
- Whether the quarter’s $137,500 intellectual-property gain and $87,500 of other income were nonrecurring.
- The collectability and aging of accounts receivable, which increased materially during the quarter.
- The extent to which operating cash flow can support growth after working-capital requirements and debt repayments.
- The ownership, valuation, patent status, and commercial prospects of the kaniwa protein extraction intellectual property.
- Potential limitations on the approximately $20.325 million of tax net operating loss carryforwards.
- Outstanding dilution from 209,808 warrants, 180,000 options, and subscribed shares.